Tags

Type your tag names separated by a space and hit enter

[The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Zhonghua Nei Ke Za Zhi. 2014 Dec; 53(12):964-8.ZN

Abstract

OBJECTIVE

To compare the efficacy and safety of long-term treatment (48 weeks) with tiotropium bromide (5 µg) via Respimat(®) with placebo in patients with chronic obstructive pulmonary disease (COPD).

METHODS

A total of 338 patients were randomized in this double-blind, placebo controlled, parallel study. All patients received either tiotropium bromide or placebo. Tiotropium bromide solution 5 µg (2×2.5 µg/puff) or matching placebo was delivered via Respimat(®) at a dosage of once daily for 48 weeks. Co-primary endpoints were trough forced expiratory volume in one second (FEV(1)) and the time to first exacerbation.

RESULTS

Statistically significant improvements of both trough FEV(1) and trough forced vital capacity (FVC) in the tiotropium group were achieved at weeks 4, 24, and 48 compared with those in the placebo group (P < 0.000 1). Tiotropium treatment delayed the time to first exacerbation. The time was 157 days in the tiotropium group and 85 days in the placebo group. A statistically significant difference (P = 0.002 7) in favor of tiotropium was also observed. The total numbers of exacerbation during treatment were 90 and 128 in the tiotropium and placebo groups, respectively. The Poisson regression analysis gave a mean exacerbation rate per patient year exposure of 0.67 in the tiotropium group compared to 0.98 in the placebo group with a rate ratio of 0.69 (95%CI 0.50-0.93, P = 0.016 4). A much larger improvement from baseline in St. George's respiratory questionnaire (SGRQ) total score was observed for the tiotropium group than in the placebo group (P = 0.036 7), SGRQ symptom and activity scores of patients in the tiotropium group were also superior to those of patients receiving placebo. The drugs-related adverse events in the tiotropium and placebo groups were 12 cases and 11 cases, respectively.

CONCLUSIONS

Tiotropium significantly improved lung function and quality of life, delayed the time to first exacerbation, reduced the number of exacerbation. Overall, tiotropium was well tolerated.

Authors+Show Affiliations

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. Email:nanshan@vip.163.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

25623564

Citation

Ma, Jinfang, et al. "[The Efficacy and Safety of Low-dose Tiotropium Bromide Inhaled Via Respimat® in Patients With Chronic Obstructive Pulmonary Disease]." Zhonghua Nei Ke Za Zhi, vol. 53, no. 12, 2014, pp. 964-8.
Ma J, Zhou Z, Tang Y, et al. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease]. Zhonghua Nei Ke Za Zhi. 2014;53(12):964-8.
Ma, J., Zhou, Z., Tang, Y., & Zhong, N. (2014). [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease]. Zhonghua Nei Ke Za Zhi, 53(12), 964-8.
Ma J, et al. [The Efficacy and Safety of Low-dose Tiotropium Bromide Inhaled Via Respimat® in Patients With Chronic Obstructive Pulmonary Disease]. Zhonghua Nei Ke Za Zhi. 2014;53(12):964-8. PubMed PMID: 25623564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease]. AU - Ma,Jinfang, AU - Zhou,Zhimin, AU - Tang,Yan, AU - Zhong,Nanshan, PY - 2015/1/28/entrez PY - 2015/1/28/pubmed PY - 2015/6/8/medline SP - 964 EP - 8 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 53 IS - 12 N2 - OBJECTIVE: To compare the efficacy and safety of long-term treatment (48 weeks) with tiotropium bromide (5 µg) via Respimat(®) with placebo in patients with chronic obstructive pulmonary disease (COPD). METHODS: A total of 338 patients were randomized in this double-blind, placebo controlled, parallel study. All patients received either tiotropium bromide or placebo. Tiotropium bromide solution 5 µg (2×2.5 µg/puff) or matching placebo was delivered via Respimat(®) at a dosage of once daily for 48 weeks. Co-primary endpoints were trough forced expiratory volume in one second (FEV(1)) and the time to first exacerbation. RESULTS: Statistically significant improvements of both trough FEV(1) and trough forced vital capacity (FVC) in the tiotropium group were achieved at weeks 4, 24, and 48 compared with those in the placebo group (P < 0.000 1). Tiotropium treatment delayed the time to first exacerbation. The time was 157 days in the tiotropium group and 85 days in the placebo group. A statistically significant difference (P = 0.002 7) in favor of tiotropium was also observed. The total numbers of exacerbation during treatment were 90 and 128 in the tiotropium and placebo groups, respectively. The Poisson regression analysis gave a mean exacerbation rate per patient year exposure of 0.67 in the tiotropium group compared to 0.98 in the placebo group with a rate ratio of 0.69 (95%CI 0.50-0.93, P = 0.016 4). A much larger improvement from baseline in St. George's respiratory questionnaire (SGRQ) total score was observed for the tiotropium group than in the placebo group (P = 0.036 7), SGRQ symptom and activity scores of patients in the tiotropium group were also superior to those of patients receiving placebo. The drugs-related adverse events in the tiotropium and placebo groups were 12 cases and 11 cases, respectively. CONCLUSIONS: Tiotropium significantly improved lung function and quality of life, delayed the time to first exacerbation, reduced the number of exacerbation. Overall, tiotropium was well tolerated. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/25623564/[The_efficacy_and_safety_of_low_dose_tiotropium_bromide_inhaled_via_Respimat®_in_patients_with_chronic_obstructive_pulmonary_disease]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0578-1426&amp;year=2014&amp;vol=53&amp;issue=12&amp;fpage=964 DB - PRIME DP - Unbound Medicine ER -